Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 369 participants.

Also called NCT02865850

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 369 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02865850
  • EudraCT 2016-000838-21
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Brazil, Germany, Italy, Mexico, Poland, Portugal, Russia, South Korea, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02865850. Randomized; no masking; primary purpose treatment. Start 2016-07 (actual); primary completion 2020-01-31 (actual). Results posted on 2022-07-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)
Condition
Anemia
Condition
Dialysis-Dependent Chronic Kidney Disease
Intervention (Drug)
Vadadustat
Intervention (Drug)
Darbepoetin alfa
Lead sponsor
Akebia Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct02865850
Content hash
75f1001ea6cc292d05fd4c99bfb574965554d517f2d7e885dd9d4ac1a0bedeff